scholarly journals Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Kaveh Naseri ◽  
Hossein Dabiri ◽  
Mohammad Rostami-Nejad ◽  
Abbas Yadegar ◽  
Hamidreza Houri ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Symptom Severity ◽  
Dietary Intervention ◽  
Gluten Free Diet ◽  
Gluten Free ◽  
Before And After ◽  
Irritable Bowel ◽  
Iranian Patients

Abstract Background and objective Recently, dietary restriction of fermentable carbohydrates (a low-FODMAP diet) in combination with a gluten-free diet (GFD) has been proposed to reduce the symptoms in irritable bowel syndrome (IBS) patients. Different studies reported that IBS has been associated with dysbiosis in the gut microbiota. Additionally, a few studies have reported inflammation in the gastrointestinal (GI) system of adults with IBS. In this study, we aimed to investigate the effects of low FODMAP-gluten free diet (LF-GFD) on clinical symptoms, intestinal microbiota diversity, and fecal calprotectin (FC) level in Iranian patients with IBS. Design In this clinical trial study, 42 patients with IBS (Rome IV criteria) underwent LF-GFD intervention for 6 weeks. Symptoms were assessed using the IBS symptom severity scoring (IBS-SSS), and fecal samples were collected at baseline and after intervention and analyzed by quantitative 16 S rRNA PCR assay. The diversity of gut microbiota compared before and after 6 weeks of dietary intervention. FC was also analyzed by the ELISA method. Results Thirty patients (mean age 37.8 ± 10.7 years) completed the 6-week diet. The IBS-SSS was significantly (P = 0.001) reduced after LF-GFD intervention compared to the baseline. Significant microbial differences before and after intervention were noticed in fecal samples. A significant increase was found in Bacteroidetes, and the Firmicutes to Bacteroidetes (F/B) ratio was significantly (P = 0.001) decreased after the dietary intervention. The value of FC was significantly decreased after 6 weeks of dietary intervention (P = 0.001). Conclusions Our study suggests that patients with IBS under an LF-GFD had a significant improvement in IBS symptoms severity, with reduced FC level following normalization of their gut microbiota composition. Further rigorous trials are needed to establish a long-term efficacy and safety of this dietary intervention for personalized nutrition in IBS. Clinical Trial Registry Number: IRCT20100524004010N26.

scholarly journals Influence of Low FODMAP and Gluten-Free Diets on Gut Microbiota Alternations and Symptom Severity in Iranian Patients With Irritable Bowel Syndrome; A Clinical Trial Study

2021 ◽  
Author(s):  
Kaveh Naseri ◽  
Hossein Dabiri ◽  
Mohammad Rostami Nejad ◽  
Abbas Yadegar ◽  
Hamidreza Houri ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Symptom Severity ◽  
Dietary Intervention ◽  
Gluten Free ◽  
Before And After ◽  
Irritable Bowel ◽  
Fodmap Diet ◽  
Iranian Patients

Abstract Background & objective: Recently, dietary restriction of fermentable carbohydrates (a low-FODMAP diet) in combination with a gluten-free diet (GFD) has been proposed to reduce the symptoms in irritable bowel syndrome (IBS) patients. Different studies reported that IBS has been associated with dysbiosis in the gut microbiota. Additionally, a few studies have reported inflammation in gastrointestinal (GI) system of adults with IBS. In this study we aim to investigate the effects of GFD and low-FODMAP diet on clinical symptoms, intestinal microbiota diversity, and fecal calprotectin (FC) level in Iranian patients with IBS.Design: In this clinical trial study, 42 patients with IBS (Rome IV criteria) underwent GFD + low-FODMAP dietary intervention for 6 weeks. Symptoms were assessed using the IBS symptom severity scoring (IBS-SSS), and fecal samples were collected at baseline and after intervention and analyzed by quantitative 16S rRNA PCR assay. The diversity of gut microbiota compared before and after 6 weeks of dietary intervention. FC was also analyzed by ELISA method.Results: Thirty patients (mean age 37.8 ± 10.7 years) completed the 6-week diet. The IBS-SSS was significantly (P = 0.038) reduced after GFD + low-FODMAP dietary intervention compared to the baseline. Significant microbial differences before and after intervention were noticed in fecal samples. A significant increase was found in Bacteroidetes, and the Firmicutes to Bacteroidetes (F/B) ratio was significantly ( P = 0.001) decreased after the dietary intervention. The value of FC was significantly decreased after 6 weeks dietary intervention (P = 0.001).Conclusions: Our study suggests that patients with IBS under a GFD + low-FODMAP diet had a significant improvement in IBS symptoms severity, with reduced FC level following normalization of their gut microbiota composition. Further rigorous trials are needed to establish long-term efficacy and safety of this dietary intervention for personalized nutrition in IBS.

Efficacy and safety of Achillea wilhelmsii C. Koch capsules on symptom severity and quality of life in patients with irritable bowel syndrome: a randomized, placebo-controlled clinical trial

2019 ◽  
Vol 16 (4) ◽  
Author(s):  
Padide Derakhshande ◽  
Seyed Jafar Navabi ◽  
Yalda Shokoohinia ◽  
Hojjat Rouhi-Broujeni ◽  
Fateme Deris ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Irritable Bowel Syndrome ◽  
Symptom Severity ◽  
Significant Difference ◽  
Before And After ◽  
The Mean ◽  
Achillea Wilhelmsii ◽  
Irritable Bowel

Abstract Background Irritable bowel syndrome (IBS) is one of the most common digestive diseases. The aim of this clinical trial was to determine the effectiveness of Achillea wilhelmsii C. Koch on the symptom severity and quality of life (QOL) in patients with IBS. Methods The patients were randomized into two groups of 45 each. The QOL and symptom severity of the patients were evaluated at baseline and at completion of the treatments by means of IBS-QOL and IBS severity index. Results The mean severity of clinical symptoms in the Achillea wilhelmsii C. Koch receiving groups before and after the treatment was 282.56 ± 103.57 and 178.06 ± 88.40, and in the placebo group was 265.93 ± 93.56 and 197.74 ± 106.26, respectively. The mean QOL in the Achillea wilhelmsii C. Koch receiving group before and after treatment was 51.49 ± 11.98 and 50.44 ± 13.39 and in the placebo group was 60.71 ± 11.97 and 58.39 ± 11.67, respectively. In both groups, there was a significant difference in the recovery rate in each group (p<0.05). However, the mean difference between the two groups before and after intervention was not significantly different (p>0.05). Also, no patient reported any adverse events during the trial. Although the symptom severity and QOL in both groups were improved compared to those before intervention, there was no significant difference between the two groups. Conclusion It is recommended to conduct future studies with larger sample size and longer treatment periods, and also investigate the efficacy on the IBS subtypes, separately.

scholarly journals Irritable Bowel Syndrome and Gluten-Related Disorders

Nutrients ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 1117 ◽  
Author(s):  
Paolo Usai-Satta ◽  
Gabrio Bassotti ◽  
Massimo Bellini ◽  
Francesco Oppia ◽  
Mariantonia Lai ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Celiac Disease ◽  
The Other ◽  
Gluten Free Diet ◽  
Gluten Free ◽  
Gut Permeability ◽  
Online Search ◽  
Systematic Screening ◽  
Wheat Sensitivity ◽  
Irritable Bowel

Background: Irritable bowel syndrome (IBS) is frequently associated with celiac disease (CD) and nonceliac gluten/wheat sensitivity (NCGS/NCWS), but epidemiological and pathophysiological aspects are still unclear. Furthermore, a gluten-free diet (GFD) can positively influence IBS symptoms. Methods: A comprehensive online search for IBS related to CD, NCGS and GFD was made using the Pubmed, Medline and Cochrane databases. Results: Although a systematic screening for CD in IBS is not recommended, CD prevalence can be increased in diarrhea-predominant IBS patients. On the other hand, IBS symptoms can be persistent in treated CD patients, and their prevalence tends to decrease on a GFD. IBS symptoms may overlap and be similar to those associated to nonceliac gluten and/or wheat sensitivity. Increased gut permeability could explain the gluten/wheat effects in IBS patients. Finally, a GFD could improve symptoms in a subgroup of IBS patients. Conclusions: The possible interplay between IBS and gluten-related disorders represents a scientifically and clinically challenging issue. Further studies are needed to confirm these data and better clarify the involved pathophysiological mechanisms.

PP37 PREVALENCE OF IRRITABLE BOWEL SYNDROME IN CELIAC PATIENTS ON GLUTEN FREE DIET

2011 ◽  
Vol 43 ◽  
pp. S425 ◽  
Author(s):  
G. Lorusso ◽  
S. Castellaneta ◽  
C. Fontana ◽  
P. Papappicco ◽  
L. Cavallo ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gluten Free Diet ◽  
Gluten Free ◽  
Irritable Bowel

OC-067 A single-blinded study evaluating the effects of a gluten-free diet in diarrhoea-predominant irritable bowel syndrome

Gut ◽  
2015 ◽  
Vol 64 (Suppl 1) ◽  
pp. A34.1-A34
Author(s):  
I Aziz ◽  
J North ◽  
N Trott ◽  
R Briggs ◽  
DS Sanders
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gluten Free Diet ◽  
Gluten Free ◽  
Blinded Study ◽  
Irritable Bowel

scholarly journals The gluten free diet in depth

2017 ◽  
Vol 1 (1) ◽  
pp. 7
Author(s):  
Caroline Kanaan
Keyword(s):  
Irritable Bowel Syndrome ◽  
Neuropsychiatric Disorders ◽  
Healthy Diet ◽  
Gluten Free Diet ◽  
Gluten Sensitivity ◽  
Gluten Free ◽  
Irritable Bowel ◽  
New Research ◽  
New Diagnosis

The gluten free diet has been gaining recognition globally and is being applied by many patients. This diet was first developed for Celiac's patients however with the emergence of a new diagnosis: non-celiac gluten sensitivity (NCGS), more patients are finding relief from their symptoms when following this diet. The symptoms of NCGS also overlap with those of Irritable Bowel Syndrome and there are studies that suggest a possible link between NCGS and neuropsychiatric disorders, like autism and others. In this presentation we will review the new research about gluten and also answer the following questions. Where is gluten found? How to remove it from the diet? How to follow a healthy diet?.

Sign in / Sign up

Export Citation Format

Share Document